An Adaptive Design Study for the Assessment of the Safety, Tolerability and Pharmacokinetics of RYI-018 after Single Dosing in Healthy Volunteers and Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Namacimab (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; First in man
- Sponsors Bird Rock Bio
- 13 Sep 2018 According to a Bird Rock Bio media release, the company announced today the it has successfully completed its final patient visit in this study.
- 13 Sep 2018 According to a Bird Rock Bio media release, study results from the clinical trial are anticipated prior to the American Society of Nephrology's "Kidney Week" in October and AASLD's The Liver Meeting 2018 in November 2018.
- 13 Sep 2018 Status changed from active, no longer recruiting to completed, according to a Bird Rock Bio media release.